natgillin/translations-raw huggingface dataset:
may be useful in treating any of the above-mentioned disorders. 
može koristit u liječenju bilo kojeg od gore navedenih poremećaja.
The process of paragraph 14, wherein said secondary amine is selected from the group consisting of piperidine, pyrrolidine, piperazine, dialkylamines, and diarylalkylamines. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni sekundarni amin se bira iz skupine koju čine piperidin, pirolidin, piperazin, dialkilamini i diarilalkilamini.
A crystalline form of the compound according to claim 6, wherein the crystalline form has XRPD peaks with a method using Cu anticathode at, at least five o angles: 7.75, 10.13, 17.03, 17.16, 18.39, 21.33, and 21.88. 
Kristalni oblik spoja prema zahtjevu 6, naznačen time da kristalni oblik ima XRPD vrhove uz postupak koji koristi Cu antikatodu kod, barem pet od slijedećih kutova: 7.75, 10.13, 17.03, 17.16, 18.39, 21.33, 1 21.88.
The antibody according to any of the preceding claims, said antibody being of IgG 2B class, and/or wherein said antibody comprises an amino acid sequence set forth in SEQ ID NO: 49, or a variant thereof, said variant having at least 90% sequence identity to SEQ ID NO: 49. 
Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeno antitijelo IgG 2B klase, i/ili gdje navedeno antitijelo sadrži aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 49.
The compound for use claim 5, wherein R1, R2, and R3 are hydrogen; 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da su R1, R2 i R3 vodik; n je 0;
Cosmetic composition according to claim 1, characterized in that the compound of general formula (I) is in the form of a salt formed with a base chosen from organic bases and inorganic bases. 
Spoj prema zahtjevu 1, naznačen time da je u obliku soli baze koja je odabrana od organskih baza i anorganskih baza.
Passive overflow device according to a preceding claim, wherein the inlet and the outlet are directly fluid coupled. 
Pasivni uređaj za prelijevanje sukladno prethodnom zahtjevu, pri čemu su ulaz 1 izlaz izravno fluidno spojeni.
A solid system for modified release in accordance with any of claims 1-6, further comprising an enteric coating. 
Čvrsti sustav za modificirano oslobađanje u skladu s bilo kojim od patentnih zahtjeva 1-6, koji dalje sadrži gastrorezistentni omotač.
The retaining member has a plurality of retaining taps 55 adjacently arranged on a circle and surrounding a "release tap" 56. 
Član za držanje ima veći broj lamela 55 koje su postavljene jedna uz drugu po prugu i okružuju "lamelu za oslobađanje" 56.
The single immunoglobulin variable domain antibody of claim 3 or claim 5, comprising the amino acid sequence of SEQ ID NO:543, wherein the PEG is a 40 kD branched PEG, and wherein the PEG polymer is linked to the D70C cysteine residue. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom iz patentnog zahtjeva 3 ili patentnog zahtjeva 5, koje sadrži aminokiselinsku sekvencu sa SEQ ID NO:543, gdje PEG je razgranati PEG od 40 kD, i gdje je PEG polimer vezan za D70C cisteinski ostatak.
by a process comprising reacting a compound of Formula IIg: 
CO N llc postupkom koji obuhvaća reakciju spoja s formulom IIg:
The beta2-adrenoceptor agonist according to claim 1, wherein the phenyl ring of structural formula I defines un-substituted, mono-substituted or di-substituted phenyl ring, wherein Z and Y may be the same or different and X is hydrido and wherein Z and X are as defined in claim 1. 
Agonist beta2-adrenoceptora prema zahtjevu 1, naznačen time da fenilni prsten iz strukturne formule I definira nesupstituirani, mono-supstituirani ili di-supstituirani fenilni prsten, pri čemu Z i Y mogu biti isti ili različiti i X je hidrido i pri čemu Z i X su kako je definirano u zahtjevu 1.
the nucleic acid of claim 3 or 12; 
(1i) nukleinske kiseline sukladno patentnom zahtjevu 3 ili 12;
Method according to claim 9, wherein the light stabilising composition exhibits an A280 that exceeds 0.05. The method according to claim 1, wherein the composition exhibits an absorption ratio A280/560 of at least 80. 
Postupak prema bilo kojem od zahtjeva 12-21, naznačen time, što pripravak pokazuje apsorpcijski omjer A280/560 od najmanje 80, poželjno od najmanje 250.
An oral dosage form according to claim 20, wherein the openings in the erodable coating are on opposing surfaces. 
. Oralni oblik doziranja u skladu s patentnim zahtjevom 20, naznačen time što otvori u erodibilnoj oblozi se nalaze na nasuprotnim stranama, t>&
A nucleic acid comprising a nucleotide sequence encoding a protein comprising SEQ ID NO: 29 or 30. 
Protein, naznačen time što ima SEQ ID NO: 29 ili 30.
providing and unrolling a coil (24) to form the top layer (6), 
(VID) - isporučivanje i odmotavanje namotaja (24) kako bi se formirao gornji sloj (6),
The BS further includes a mapping module 703 . The mapping module 703 is adapted to establish a corresponding relationship between an uplink resource index and at least one uplink resource in terms of indication. 
BS prema zahtjevu 10, naznačena time da se nadalje sastoji od modula za mapiranje (703) koji je prilagođen za ostvarivanje odgovarajućeg odnosa između indeksa resursa za uzlaznu vezu i barem jednog resursa za uzlaznu vezu u smislu porijekla.
A method according to claim 1, wherein the binder is provided in dry form. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 7 ili 9 do 13, pri čemu je vezivno sredstvo dobiveno u suhom obliku.
Forty-five minutes after dosing rats were anaesthetized with sodium pentobarbital (40 mg/kg, i.p.) 
45 minuta nakon doziranja štakori su anestezirani s natrijevim pentobarbitalom (40 mg/kg, i.p.)
t is 1,2 or 3; and R9 are each independently selected from hydrogen, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl, alkoxy, aryloxy, or halogen; 
Rg i Ry su nezavisno odabrani od vodika, alkila, cikloalkila, alkenila, arila, heterociklila, alkoksi, ariloksi, ili halogena; ili njegova farmaceutski prihvatljiva sol ili solvat.
Consequently, in another aspect, the present invention relates to the antibody of the invention for use in a method of for sensitizing tumor cells in a patient for the treatment with a chemotherapeutic drug or with radiotherapy. 
Vežuća molekula koja se može vezati na LI u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je namijenjena upotrebi u postupku sensibiliziranja tumorskih stanica kod pacijenta radi liječenja kemoterapijskom lijekom ili radioterapijom.
The base station apparatus according to claim 1, wherein DVRBs with non-consecutive DVRB numbers are mapped to two of the PRBs that are adjacent to each other in the frequency domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
secondary phases to 30% by weight, 
O do 30% po težini reaktivni aluminati
Both the inlet side 23 of the thermoblock 4 and the inlet side 24 of the thermoblock 3 can be selectively put in fluid connection with evacuation outlet 13, 12, respectively, by actively controlling valve means 16, 17 in their respective opened states. 
I izlaznu stranu 23 termobloka 4 i izlaznu stranu 24 termobloka 3 može se selektivno staviti u fluidni kontakt s izlazom za pražnjenje 13 odnosno 12 aktivnim kontroliranjem ventila 16 i 17 u njihovom odgovarajućem otvorenom stanju.
Use of a composition according to claim 5 or 6, wherein the pathogens are selected from the group comprising Botrytis spp., Penicillium spp., Pezicula spp. 
Uporaba pripravka u skladu s patentnim zahtjevom 5 ili 6, naznačena time, da su patogeni odabrani iz skupine koju čine: Botrytis spp., Penicillium spp., Pezicula spp.
shredding and drying said solid fraction, so as to obtain a dried material having a water content of less than 2% and a cellulose content of less than 2%; 
drobljenja i sušenja navedene krute frakcije, zbog dobivanja osušenog materijala sa sadržajem vode manjim od 2% i sadržajem celuloze manjim od 2%;
A process for the preparation of a compound of the formula (15): by reacting a compound of the formula (14) with a Wittig reagent MePPh3Br in the presence of potassium tert-butoxide in THF. 
Postupak za pripravu spoja formule (15): [image] reakcijom spoja formule (14) s Wittingovim reagensom MePPh3Br u prisutnosti kalij tert-butoksida u THF.
The product for use according to claim 29, wherein the interval is from 1 to 12 hours. 
Produkt za uporabu u skladu s patentnim zahtjevom 29, naznačen time, da interval jest od 1 do 12 sati.
Embodiment 10. Process according to Embodiment 9, characterized in that the submerged condenser is of the shell and tube type and that the high pressure fluids are on the shell side. 
Postupak sukladno zahtjevu 7, naznačen time što je uronjeni kondenzator tipa sa cjevnim omotačem 1 cjevima i da su tekućine pod visokom tlakom na strani cjevnog omotača.
When, starting from the closed beverage production state as shown in Fig. 7, the mobile brewing head support 7, driven by the motor 12 is moved upwards again, the capsule holder 21 will not immediately follow this movement due to an interaction of the capsule holder 21 with the steering axis 22. 
Kada se, polazeći od zatvorenog položaja za proizvodnju napitka, kao što je prikazano na slici 7, nosač pomične glave za pripremanje napitka 7, kojega drži u pogonu motor 12, pomiče opet prema gore, držač čahure 21 ne će odmah slijediti to kretanje zbog međusobnog djelovanja držača čahure 21 s osovinom za upravljanje 22.
Preparation of the compounds of formula X 
Broj objave europskog patenta:
wherein the molecule is capable of binding to, inducing aggregation of or down-regulating the biological function of said protein and wherein binding of the molecule to said protein, aggregation of said protein or downregulation of the biological function of said protein in the pathogenic organism kills the pathogenic organism or inhibits the growth and/or reproduction of the pathogenic organism; for use as an antipathogenic compound in treatment of an infectious disease caused by the pathogenic organism. 
pri čemu se molekula može vezati, inducirajući agregiranje ili spuštanje regulacije biološke funkcije navedenog proteina i pri čemu se vezanje molekule na navedeni protein, agregacija navedenog proteina ili smanjenje regulacije biološke funkcije navedenog proteina u patogenim organizmima ubija patogenog organizma ili inhibira rast i / ili reprodukciju patogenog organizma; za uporabu kao antipatogeni spoj u liječenju zarazne bolesti uzrokovane patogenim organizmom.
System 10 can be adjusted up or down relative to the swath by conventional operation of the three-point hitch. 
Sustav 10 može se podizati ili spuštati u odnosu na otkos konvencionalnim funkcioniranjem spojnice s tri priključne tačke.
The compound of formula (I) as defined in claim 13 for use according to claim 13, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof. 
Spoj prema zahtjevu 1 ili zahtjevu 2, za upotrebu prema zahtjevu 8, naznačen time da stanje je giht, povratni napad gihta, gihtični artritis, hiperuricemija, hipertenzija, kardiovaskularna bolest, koronarna srčana bolest, Lesch-Nyhanov sindrom, Kelley-Seegmillerov sindrom, bolest bubrega, bubrežni kamenci, zatajenje bubrega, upala zglobova, artritis, urolitijaza, plumbizam, hiperparatireoidizam, psorijaza, sarkoidoza, nedostatak hipoksantin-gvanin-fosforiboziltransferaze (HPRT) ili njihove kombinacije.
A study was carried out to assess the effect, of Isomer B in this transgenic mouse model of Huntington's disease by assessing animals in a battery of behavioural tests. 
Provedeno je proučavanje da bi se ocijenio učinak Izomera B u transgenskom mišjem modelu Huntington-ove bolesti ocjenjivanjem niza testova ponašanja. HR P20080677 T3 Postupci
at least one fixing upright which overlaps and connects the fixing element to the base fixing element associated with said lower panel. A turret according to claim 1, wherein said half-shells define, by meeting and widening, at least one lateral edge border, which is arranged on the side of said casing (12). 
Kupola u skladu s patentnim zahtjevom 1 ili 2, naznačena time što navedene poluljuske (30, 32) definiraju, svojim sastajanjem i proširivanjem, najmanje jednu granicu bočnog ruba (344), koja se nalazi na strani navedene oplate (12).
This reinforcement layer provides added strength to the wall elements in order to provide resistance against external forces, such as wind or the like. 
Ovaj sloj za ojačanje osigurava dodatno ojačanje zidnim elementima kako bi se osigurala otpornost na vanjske sile kao što su vjetar i sl.
IPAc (850 mL) was added and the mixture was heated to 60° C. to dissolve some of the solids. 
IPAc (850 mL) je bio dodan i smjesa je bila zagrijana do 60*C da bi se otopilo nešto krutine.
Salt according to claim 5, which is rosuvastatin (-)-1-[(4-chlorophenyl)-phenyl-methyl]piperazinium salt which exhibits a powder x-ray diffraction pattern measured using CuKa-radiation having characteristic peak locations of 3.9, 10.0 and 16.9 ± 0.2 degrees 2θ, preferably 3.9, 10.0, 16.5, 16.9, 20.2 and 23.2 ± 0.2 degrees 2θ, and more preferably exhibits a powder x-ray diffraction pattern substantially as shown in Fig. 3. 
Sol prema zahtjevu 5, naznačena time, da je to rosuvastatin-(-)-1-[(4-klorofenil)-fenil-metillpiperazin-sol koja prikazuje uzorak difrakcije praha X-zraka mjeren uporabom CuKa-radijacije, s mjestima karakterističnih vršnih vrijednosti na 3,9, 10,01 16,9 +0,2 stupnjeva 20, poželjno na 3,9, 10,0, 16,5, 16,9, 20,2 i 23,2 +0,2 stupnjeva 20, i još bolje pokazuje uzorak difrakcije praha X-zraka uglavnom kako je prikazano na slici 3.
Method of forming a security document (1) comprising the steps of: 
Postupak pravljenja sigurnosnog dokumenta (1), naznačen time što se sastoji u koracima:
Use of the filler of claim 8 in metal matrix syntactic foams. 
Uporaba punila sukladno patentnom zahtjevu 8 u sintaktičkim pjenama metalne matrice.
The cell of claim 11, wherein the mammalian cell is a photoreceptor cell, a retinal rod cell, a retinal cone cell, a retinal ganglion cell, a bipolar neuron, a ganglion cell, a pseudounipolar neuron, a multipolar neuron, a pyramidal neuron, a Purkinje cell, or a granule cell; or 
Stanica iz patentnog zahtjeva 11, pri čemu je stanica sisavca a) stanica fotoreceptor, štapićasta stanica retine, čunjasta stanica retine, ganglijska stanica retine, bipolarni neuron, ganglijska stanica, pseudounipolarni neuron, multipolarni neuron, piramidalni neuron, Purkinjeova stanica, ili granulirana stanica; ili b) stanica melanoma, COS stanica; BHK stanica, HEK293 stanica, CHO stanica, stanica mijeloma, ili MDCK stanica.
Example 2: Elucidation of the adduct: 
Datum objave europske prijave patenta:
detecting with the processor mechanism at least a first user marking cell on the form, wherein the first user marking cell is bounded by at least one indicium that is visible to the camera, and wherein the first user marking cell is detected based at least in part upon the calculated distance between the first fiducial mark and the second fiducial mark; 
detektiranju procesorskim mehanizmom u najmanju ruku prve ćelije za korisničku oznaku na formularu (400, 700) na temelju u najmanju ruku dijelom izračunatog razmaka između prve položajne oznake (401a,701a) i druge položajne oznake (401b, 701b), gdje je prva ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru;
The composition of claim 3, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO:23. The composition of claim 11, wherein the 4-1BB costimulatory signaling region of the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:17. 
(v) anti-CD19 scFv je kodirano sekvencom SEQ ID NO: 14, signalno područje 4-1BB je kodirano sekvencom SEQ ID NO: 17 i signalna domena CD3 zeta je kodirana sekvencom SEQ ID NO: 15; ili
Although not being bound by theory, it is believed that the structure of the matrix (e.g. a hydrogel) results in there being less water and fewer free ions (particularly hydroxyl ions) to initiate hydrolysis. 
Iako bez vezivanja za teoriju, vjeruje se da struktura matriksa (npr., hidrogel) ima za rezultat manju količinu vode u strukturi i manje slobodnih iona (posebno hidroksil iona) da započnu hidrolizu.
Use according to claim 13 characterized in that said phospholipids have a greater than 97% degree of acetone insolubility. 
Uporaba prema zahtjevu 15 naznačena time što polarni fosfolipidi imaju stupanj netopljivosti u acetonu veći od
MEP-Hypercel® is a resin that is particularly suitable in the frame of the present invention. 
MEP-Hypercel" je nosač koji je posebice prikladan za ovaj izum.
A substance that inhibits specific binding of HGF B chain to c-met, wherein the substance is: 
Tvar koja inhibira specifično vezanje HGF f lanca na c-met, naznačena time, da spomenuta tvar je:
A compound of the formula I: and N-oxides, salts, and stereoisomers thereof 
Spoj formule I: i njegovi N-oksidi, soli, i stereoizomeri naznačen time da
A process for the preparation ofmemantine hydrochloride, comprising: reacting 1-halo-3,5-dimethyladamantane and a nitrile in the presence of phosphoric acid at a temperature of 50° to 100°C for a sufficient period of time to obtain n-acetamido-3,5-dimethyladamantane; and converting the n-acetamido-3,5-dimethyladamantane to memantine hydrochloride. A process for the preparation ofmemantine hydrochloride, comprising: 
Postupak dobivanja memantin-hidroklorida, naznačen time što se sastoji u: reakciji 1-halogen-3,5- dimetiladamantana s nitrilom, u prisutnosti fosforne kiseline, na temperaturi od 50 *C do 100 *C, kroz dovoljno dugo vrijeme da se dobije n-acetamido-3,5-dimetiladamantan; te u prevođenju n-acetamido-3,5-dimetiladamantana u memantin-hidroklorid.
the bacterial toxoid is diphtheria toxoid, or a derivative thereof; or 
bakterijski toksoid je difterijski toksoid, ili njegov derivat; ili
The system of claim 17 wherein the magnetic system further comprises a first set of mirror coils positioned between the ends of the confinement chamber and the first and second formation sections. 
Sustav prema zahtjevima 1, 4 i 5, naznačen time, da dodatno obuhvaća treći i četvrti komplet zrcalnih zavojnica između svakog od prvog i drugog tvorbenog dijela (200) te prvog i drugog preusmjerivača (300).
The compounds of formula I also inhibited glycinamide ribonucleotide transformylase in a comparable concentration range to methotrexate. 
Spojevi formule I također inhibiraju glicinamid ribonukleotid transformilazu u usporedivom koncentracijskom rasponu kao metotreksat.
Thus, the effect of loading CCM at pH 6.1 instead of pH 7.2 was investigated. 
Prema tome je istražen efekt nanošenja CCM na kolonu pri pH 6.1 umjesto 7.2.
In this embodiment, aerosol generating means 12 includes a thermally stable conductive carbonaceous substrate 30, such as a plug of porous carbon, which is impregnated with an aerosol forming substance or substances. 
U ovoj realizaciji, sredstvo 12 za generiranje aerosola uključuje termički stabilan provodljiv ugljični supstrat 30, kao što je čep od poroznog ugljika, koji je impregniran sa supstancom ili supstancama za formiranje aerosola.
The composition according to claim 25, wherein the viral infection is hepatitis C virus. 
Pripravak u skladu s patentnim zahtjevom 25, naznačen time, da je virusna infekcija virus hepatitisa C.
The formula ingredients were dispersed together and the viscosity of the resulting mixture was adjusted with deionised water to reach the value of 20-40 s DIN4 at 25°C. 
Sastojci formule se zajedno rasprše, a viskozitet dobivene mješavine se prilagodi deioniziranom vodom kako bi se dobila vrijednost od 20-40 s DIN4 na temperaturi od 25%C.
The process of embodiment 26, comprising a measurement step before mixing of the conjugates and/or a measurement step after mixing the conjugates. 
Postupak prema zahtjevu 26, naznačen time da sadrži korak mjerenja prije miješanja konjugata i/ili korak mjerenja nakon miješanja konjugata.
2a) Performing a set partitioning on the first data-set in order to obtain a hierarchical, multilevel tree which comprises a plurality of first data-subsets; 
provedbe particioniranja niza na prvom podatkovnom nizu kako bi se dobilo hijerarhijsko, višerazinsko stablo koje sadrži više prvih podatkovnih podnizova;
and/or in the process for preparing compound 4, the hydrogenation temperature is in the range of 0-60° C.; 
i / ili u postupku pripreme spoja 4, temperatura hidrogeniranja je u rasponu od 0-60°C;
Process according to claim 4 characterized in that the compound obtained is enantiomerically pure (S)-pirlindole (R)-(+)-a-methoxy-a-trifluoromethylphenylacetate salt. 
Proces u skladu sa patentnim zahtjevom 4 naznačen time da dobiveni spoj je enantiomerno čista (S)-pirlindol (R)-(+)-a-metoksi-a-trifluorometilfenilacetat sol.
a second separation step S 2 ′ which consists in the separation of fraction F 2 into fraction A and into a fraction F 2 ′, and 
- < drugi korak odvajanja S2' koji se sastoji u odvajanju frakcije F2 u frakciju A i u frakciju F2', te
The mouse of claim 20, wherein the isoenyzme is a protein selected from the group consisting of any one of SEQ ID NOS: 15-25 or an analogue thereof having at least 50% / 75% sequence identity / similarity. 
Miš u skladu s patentnim zahtjevom 20, naznačena time što je izoenzim protein, kojeg se bira iz skupine koju čine bilo koji od SEQ ID NO: 15-25.
The antibody or antigen binding fragment of claim 2, wherein the antibody or antigen binding fragment comprises the polypeptide sequences of SEQ ID NO:57 and SEQ ID NO:74. The immunoconjugate of claim 5, wherein said linker is SMCC. 
Imunokonjugat iz patentnog zahtjeva 7, gdje (A) je antitijelo ili njegov antigen-vezujući fragment koji sadrži polipeptid sa SEQ ID NO:58 i polipeptid sa SEQ ID NO: 74, gdje (L) je SMCC, i gdje (C) je DMI.
The isolated cell of claim 9, wherein the cell expresses the chimeric human/non-human MHC I polypeptide on its surface. 
Izolirana stanica prema zahtjevu 9, naznačena time, da stanica na svojoj površini eksprimira kimerni ljudski/neljudski MHC-I-polipeptid.
A compound or salt for use according to claim 22, wherein:- said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder; or 
Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da a) navedena autoimuna bolest predstavlja poremećaj na koži, multiplu sklerozu, reumatoidni artritis, psorijazni artritis, juvenilni artritis, dijabetes tip I, lupus, upalnu bolest crijeva, Crohnovu bolest, mijasteniju gravis, imunoglobulinsku nefropatiju, miokarditis, ili autoimuni poremećaj štitnjače; ili b) navedena autoimuna bolest predstavlja reumatoidni artritis; ili
The method according to claim 1, wherein L is NH. 
Spoj prema zahtjevu 1, pri čemu L je NH.
The overall telegram so formed is transmitted over serial transmission channel 10a, 10b at a transmission speed of four times the frequency used to transmit data to the beacons. 
Cjeloviti, tako formirani telegram se prenosi preko serijskog prijenosnog kanala 10a, 10b pri prijenosnoj brzini od četverostruke upotrebljene frekvencije za prijenos podataka prema balizama.
However, instead of subjecting the compound (II) to hydroboration, the 2,3-double bond is converted to an epoxide by reaction with meta -chloroperbenzoic acid (MCPBA) and perchloric acid. 
Naravno, umjesto podvrgavanja spoja (II) hidroboriranju, 2,3-dvostruka veza je prevedena u epoksid reakcijom s meta-kloroperbenzojevom kiselinom (MCPBA) i perklornom kiselinom.
wherin the receiving device comprises: 
- pri čemu prijemni uređaj sadrži: